The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma. Mooradian MJ, Sullivan RJ. Cancer 2023;129:2117-2121.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Mooradian MJ, Sullivan RJ. The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma. Cancer 2023;129:2117-2121.
PMID: 37345669